US FDA approves Axsome's drug for Alzheimer's-related agitation
30/04/2026 19:08
Corrects day to Thursday April 30 (Reuters) - The U.S. Food and Drug Administration has approved Axsome Therapeutics' AXSM.O drug to treat agitation in patients with Alzheimer's disease, the company said on Thursday. (Reporting by Kamal Choudhury, Mariam Sunny and Siddhi Mahatole in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Axsome Therapeutics
See all newsUS RESEARCH ROUNDUP-Bright Minds Biosciences, Marvell Technology, Oracle Corporation
Axsome Therapeutics Q3 revenue rises on Auvelity and Sunosi
US RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Axsome Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Axsome Therapeutics Q2 revenue rises on AUVELITY growth